Factor VIII (FVIII) treatment has more than
50 years of use and over 175 clinical studies.1,2
Count on factor VIII (FVIII) prophylaxis to be there.
Your patients are unique-so they
deserve an individualized treatment.
Establishing a routine with
Factor VIII (FVIII) may
empower patients.
FVIII: DECADES OF EXPERIENCE TREATING HEMOPHILIA A PATIENTS
Your patients with hemophilia A all live different lives, but they likely have one goal in common: prevent and control bleeds. FVIII has supported patients with hemophilia A for decades, and it remains the only hemophilia A treatment approved for prophylaxis, on-demand, and surgical use.3
Experience replacing what’s missing
FVIII works by replacing the clotting factor that is missing in patients with hemophilia A, or classic hemophilia.4
With intravenous factor infusion, the proteins needed for clotting are immediately available for use, which allows for bleed control and bleed prevention.5
In surgery and acute bleeds, FVIII remains a standard of care
FVIII is recommended for maintaining hemostasis during and after operating procedures. Furthermore, acute bleeds in certain locations may be life-threatening and need to be addressed immediately with on-demand attention.5
FVIII can help meet the bleed prevention and control needs of your patients. FVIII is the only treatment with three indications3:
- Prophylaxis
- On-demand
- Surgical use
A history of reducing joint and target joint bleeding
In a prospective, cross-sectional, longitudinal study of patients aged 2 to 69, FVIII was shown to be effective in reducing joint bleeding rates, total bleeding rates, and target joint bleeding in all age groups regardless of the age of initiation.6*
*n=26,614 HTC visits, n=6196 patients
Prophylaxis and joint health
In addition to reducing clinically evident joint bleeds in patients with hemophilia, it has been proposed that FVIII prophylaxis may help in reducing subclinical bleeds that could result in joint deterioration.6,7
Safety Considerations
As with all medications, FVIII products also carry some risks. Counsel patients on the associated risks and what to do if they occur.
Allergic Reactions
Hypersensitivity reactions, including severe allergic reactions, are possible. Early signs of an allergic reaction that can progress to anaphylaxis may include: angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus.8 Should these signs occur, discontinue use, and initiate appropriate treatment.
Factor VIII inhibitors
Development of FVIII inhibitors is also possible. Monitor all patients for the development of FVIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma FVIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures FVIII inhibitor concentration.5
Adverse reactions have been reported with all factor products. For additional safety information pertaining to a specific product, please refer to the product's full Prescribing Information.
References:
1. NIH Clinical Trials Registry. Ongoing and complete clinical trials using factor in patients with hemophilia. Accessed September 30, 2021. https://clinicaltrials.gov/ct2/results/details?cond=Hemophilia&term=Factor+VIII&cntry=&state=&city=&dist=&Search=Search&recrs=e&fund=2 2. Food and Drug Administration. User fee billable biologic products and potencies approved under Section 351 of the PHS Act. Accessed September 30, 2021. https://www.fda.gov/media/113210/download 3. Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479-486. 4. Hemophilia A. National Hemophilia Foundation. Accessed September 30, 2021. https://www.hemophilia.org/bleeding-disorders-a-z/types/hemophilia-a 5. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd ed. Haemophilia. 2020;26(suppl 6):1-158. 6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544. 7. Berntorp E. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens. Haemophilia. 2009;15(6):1219-1227. 8. Allergic reactions to factor concentrate. Hemophilia of Georgia. Accessed September 30, 2021. https://www.hog.org/handbook/article/3/35/allergic-reactions-to-factor-concentrate